Organ-specific mitochondrial heterogeneity: An under-recognized variable in preclinical drug toxicity screening.
Key Insights
- Mitochondria exhibit substantial organ-specific heterogeneity arising from the distinct physiological, metabolic, and functional demands of individual organs.
- Differences in bioenergetics, oxidative stress handling, calcium homeostasis, and metabolic adaptability may influence mitochondrial response.
Show formatted citation
@misc{ acaciacompliance-research-organ-specific-mitochondrial-heterogeneity-an-under-recogniz,
title = { Organ-specific mitochondrial heterogeneity: An under-recognized variable in preclinical drug toxicity screening. },
author = { N Lal },
year = { 2026 },
doi = { 10.1016/j.mito.2026.102199 },
url = { https://pubmed.ncbi.nlm.nih.gov/42551501/ },
note = {Summarized and classified by AcaciaFund}
}
TY - GEN TI - Organ-specific mitochondrial heterogeneity: An under-recognized variable in preclinical drug toxicity screening. AU - N Lal PY - 2026 DO - 10.1016/j.mito.2026.102199 UR - https://pubmed.ncbi.nlm.nih.gov/42551501/ ER -
Edit on GitHub — registry.json
Overview
Mitochondria exhibit substantial organ-specific heterogeneity arising from the distinct physiological, metabolic, and functional demands of individual organs. Differences in bioenergetics, oxidative stress handling, calcium homeostasis, and metabolic adaptability may influence mitochondrial responses to pharmacological agents and contribute to organ-selective drug toxicity. However, contemporary preclinical drug toxicity screening continues to rely predominantly on generalized experimental syste
Key Topics
- Aml: A theme covered by this item within the AML and compliance context.
- Transaction Monitoring: A theme covered by this item within the AML and compliance context.
Why It Matters
This item adds to the AML and compliance knowledge base. Practitioners can use it to stay current on Organ-specific mitochondrial heterogeneity: An under-recognized variable in preclinical drug toxicity screening, but should validate its claims against primary sources and more recent work before relying on it in production decisions.
Key Takeaways
- Understand how Organ-specific mitochondrial heterogeneity: An under-recognized variable in preclinical drug toxicity screening relates to AML and compliance workflows and controls.
- Assess evidence quality and freshness before acting on the findings.
- Use the tagged topics to connect this item to related content in the library.